The Vall d´Hebron Institute of Oncology (VHIO) Seeks a “Data-Software Engineer”
Reference: Ref. 83-2023
Application deadline: until position fillied.
Number of vacancies: 1
The Oncology Data Science Group is seeking a data-software engineer to design and manage databases, develop new tools, mobile and web applications for clinical research and perform software integrations between different platforms. Applicants must have a degree in Data Engineering, Software Engineering or Computer Science, and those with degrees in Biomedical Engineering, Bioinformatics, or other related fields will be considered if they have proven experience in programming, data management and software development.
It is critical for applicants to stay up to date with the latest developments in systems and coding, self-learn new technologies, and gradually become more autonomous. The ideal candidate will be able to work independently as well as collaboratively with the team.
The selected candidate will have the opportunity to work in a dynamic and challenging environment with cutting-edge technologies and to contribute to the development of innovative solutions for oncology research.
- ETL, Data Integration and Data quality
- Analyse, design and develop new tools, mobile and web applications for clinical research.
- Provide ongoing maintenance, support and enhancements in existing systems and platforms.
- Provide recommendations for continuous improvement.
- Degree in Software Engineering or Computer science is essential. Applicants with degrees in biomedical engineering, bioinformatics or other related fields will be considered as long as they can prove experience in programming and software development.
- A passion for solving problems and providing workable solutions.
- Strong analytical and reasoning skills with an ability to visualise processes and outcomes.
- Outstanding communication skills and ability to work in a cross-disciplinary team.
- Fluent technical communication skills in English.
- Experience in modern programming object-oriented languages, especially Python.
- Experience with relational databases and SQL.
- Experience working within ETL and Data Integration
- Experience within Data Integration and common challenges faced with diverse data sets and data quality
- Experience with API integrations.
- Experience working with infrastructure automation technologies like Docker.
This role involves working closely with the Early Clinical Drug Development team on various projects, including the UpSMART initiative. UpSMART aims to enhance experimental cancer development across the United Kingdom, Italy, and Spain by providing early-phase clinical teams with digital healthcare products that enable real-time access to patient data, allowing for quicker decision-making.
More information of the Oncology Data Science Group
More information of the Early Drug Development Group
More information of the UpSMART project
Potential candidates should submit a curriculum vitae and a letter of intent via email to firstname.lastname@example.org, including the reference “Ref. 83-2023” in the subject line of your email.
Under the leadership of Josep Tabernero, the Vall d’Hebron Institute of Oncology (VHIO), has established itself as a comprehensive cancer center of proven excellence internationally. It is also thanks to VHIO’s optimal organizational structure based on a purely multidisciplinary and translational model that VHIO talents continue to anticipate and tackle the many unresolved questions in combatting this multifaceted and heterogeneous disease.
Located within the Vall d’Hebron Barcelona Hospital Campus, our researchers closely collaborate and interact with Vall d’Hebron physician-scientists. Translational science and clinical research are therefore tightly connected which promotes superb interaction and teamwork which, in turn, accelerates the bench-bedside-bed cycle of knowledge. This privileged environment affords VHIO direct access to patients as well as the entire spectrum of oncology professionals who care for them, and a second-to-none appreciation of how cancer science can translate into more powerful, targeted treatments and better practice for the care of patients.
VHIO’s pioneering model and programs, coupled with its belief in combining strengths through cross-border collaborations, continue to spur advances in reversing cancer resistance, halting metastatic spread, and more effectively treating even the most undruggable tumor types.